The Journal of Urology
Volume 182, Issue 2 , Pages 425-426 , August 2009

Prognostic Implications of Polymorphisms and Interleukin-2 Therapy for Renal Cell Carcinoma

  • Thomas A. Gardner

      Affiliations

    • Department of Urology, Indiana University Simon Cancer Center and Walther Oncology Center, Indianapolis, Indiana
    • ,
  • Theodore Logan

      Affiliations

    • Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana

References 

  1. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802
  2. Leibovich BC, Sheinin Y, Lohse CM, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25:4757
  3. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11:3714
  4. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461
  5. McDermott DF, Atkins MB. Immunotherapy of metastatic renal cell carcinoma. Cancer. 2008;14:320
  6. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer. 1986;38:489
  7. van Dijk J, Warnaar SO, van Eendenburg JD, et al. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen. Int J Cancer. 1989;43:344
  8. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993;11:738
  9. Davis ID, Wiseman GA, Lee FT, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 2007;7:13
  10. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075
  11. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746
  12. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56:27
  13. Lerner M, King C, Logan T et al: Retrospective comparison of metastatic tumor volume to primary tumor volume in patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma. Unpublished data.

PII: S0022-5347(09)01260-9

doi: 10.1016/j.juro.2009.05.073

The Journal of Urology
Volume 182, Issue 2 , Pages 425-426 , August 2009

Article Tools